Retina UK awarded prestigious quality standard
The Royal National Institute of Blind People (RNIB) have awarded Retina UK the Visibly Better Employer quality standard.
Search
Search results
Research grant awards worth £870K announced
Retina UK is delighted to announce that it has awarded three new research grants worth more than £870,000.
Vitamin A supplements provides no vision benefit to RP patients
Research determines that taking high dose vitamin A supplements does not slow vision loss in people with retinitis pigmentosa (RP).
Gene Therapy improves functional measures in XLRP
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
Nanoscope Announces topline results from randomised phase 2B trial of MCO-010 for retinitis pigmentosa
Nanoscope Therapeutics has announced positive results from their two year randomised controlled phase 2b optogenetic therapy trial for late-stage retinitis pigmentosa (RP).
Phase 3 clinical trial has been given approval by FDA
The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).
Grant from The National Lottery Community Fund
We regularly make applications for grants to fund our information and support projects and have recently been successful in securing £12,000 from The National Lottery Community Fund.
New Gene Insertion Therapy for Stargard Disease in Development
SalioGen Developing Novel Gene Insertion Therapy for Stargardt disease.
New Young Persons Project from Retina UK
We are proud to launch our new Young Persons Project, which will play a significant role in providing impactful and timely support for young people with inherited sight loss and mental health challenges, across the UK.
CRISPR Gene Editing Leads to Improvements
CRISPR gene editing leads to improvements in vision for people with inherited blindness, clinical trial shows.